4-HO-EPT
| Summary sheet: 4-HO-EPT |
| 4-HO-EPT | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||
| Common names | 4-HO-EPT, Eprocin | ||||||||||||||||
| Substitutive name | 4-hydroxy-N-ethyl-N-propyltryptamine | ||||||||||||||||
| Systematic name | 3-[2-(Ethylpropylamino)ethyl]-4-indolol | ||||||||||||||||
| Class Membership | |||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||
| Chemical class | Tryptamine | ||||||||||||||||
| Routes of Administration | |||||||||||||||||
|
|||||||||||||||||
| Interactions | |||||||||||||||||
| Cannabis | |||||||||||||||||
| Stimulants | |||||||||||||||||
| Tramadol | |||||||||||||||||
| Lithium | |||||||||||||||||
4-Hydroxy-N-ethyl-N-propyltryptamine (also known as 4-HO-EPT or Eprocin) is a novel synthetic psychedelic substance of the tryptamine chemical class that produces psychedelic effects when administered. It is structurally related to psilocin (4-HO-DMT), the active component in psilocybin mushrooms, and produces similar effects.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-EPT. It has no history of human use before being sold online as a research chemical in 2016.[citation needed] It remains obscure and is either used recreationally or for research purposes.
Unlike other more popular 4-subbed tryptamines, Eprocin isn't really visual, it mostly enhances colors and makes them more "neon-ish". It has a strong euphoric body high (some users compare it to opiate body feelings). Mindset is usually light and positive.
Chemistry
4-HO-EPT, or 4-hydroxy-N,N-diethyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-EPT is substituted at R4 of its indole heterocycle with a hydroxyl functional group OH−. It also contains a propyl and ethyl chain bound to the terminal amine RN of its tryptamine backbone (EPT).
Pharmacology
Like with most psychedelic tryptamines, 4-HO-EPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-HO-EPT's binding efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Subjective effects
 |
This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it. |
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a research literature based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be regarded with a healthy degree of skepticism. It is worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include addiction, serious injury, or death.
Physical effects 
Visual effects 
-
Enhancements
Distortions
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Tracers
- After images
- Brightness alteration
- Diffraction
Geometry
Hallucinatory states
Cognitive effects 
Auditory effects 
Experience reports
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 4-HO-EPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-EPT is a research chemical with very little history of human usage.
Anecdotal evidence from people within the community who have tried 4-HO-EPT suggests that there are no negative health effects attributed to simply trying the it by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
4-HO-EPT is not habit-forming, and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.
Tolerance to the effects of 4-HO-EPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-EPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-EPT all psychedelics will have a reduced effect.
Dangerous interactions
Although many psychoactive substances are reasonably safe to use on their own, they can suddenly become dangerous or even life-threatening when combined with other substances. The following list includes some known dangerous combinations (although it is not guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 4-HO-EPT. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
- Tramadol - Tramadol is well-documented to lower the seizure threshold[1] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Due to its relative obscurity, the possession and sale of 4-HO-EPT is unscheduled in most countries.
- Germany: 4-HO-EPT is controlled under the NpSG[2] (New Psychoactive Substances Act) as of July 18, 2019.[3] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[4][5] The legislator considers it possible that orders of 4-HO-EPT are punishable as an incitement to place it on the market.[6]
- Switzerland: 4-HO-EPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.[7]
- United Kingdom: 4-HO-EPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[8]
- United States: 4-HO-EPT is unscheduled in the United States. It may be considered an analogue of psilocin (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]
See also
External links
References
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- ↑ "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095.
- ↑ "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- ↑ "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- ↑ "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- ↑ "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.